Organovo (NASDAQ:ONVO) Earns Sell Rating from Analysts at StockNews.com

Research analysts at StockNews.com started coverage on shares of Organovo (NASDAQ:ONVO) in a report issued on Saturday. The brokerage set a “sell” rating on the medical research company’s stock.

Organovo Stock Up 8.4 %

ONVO opened at $1.03 on Friday. The firm has a market capitalization of $10.34 million, a P/E ratio of -0.47 and a beta of 0.87. The stock’s 50 day moving average price is $1.04 and its two-hundred day moving average price is $1.12. Organovo has a 12-month low of $0.89 and a 12-month high of $2.05.

Organovo (NASDAQ:ONVO) last announced its quarterly earnings results on Thursday, February 8th. The medical research company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.01. The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.08 million. As a group, analysts anticipate that Organovo will post -1.74 earnings per share for the current year.

About Organovo

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.